A Three Way Crossover, Randomised, Open-Label Study in Healthy Subjects, Designed to Compare the Bioavailability of a KD025 Tablet Formulation Administered in the Fed and Fasted States and to Assess the Relative Bioavailability of a Tablet and Capsule Formulation in the Fed State

Trial Profile

A Three Way Crossover, Randomised, Open-Label Study in Healthy Subjects, Designed to Compare the Bioavailability of a KD025 Tablet Formulation Administered in the Fed and Fasted States and to Assess the Relative Bioavailability of a Tablet and Capsule Formulation in the Fed State

Completed
Phase of Trial: Phase I

Latest Information Update: 29 Jan 2016

At a glance

  • Drugs KD 025 (Primary) ; KD 025 (Primary)
  • Indications Autoimmune disorders; Graft-versus-host disease; Non-alcoholic steatohepatitis; Plaque psoriasis; Rheumatoid arthritis; Systemic lupus erythematosus
  • Focus Pharmacokinetics
  • Sponsors Kadmon Corporation
  • Most Recent Events

    • 13 Jan 2016 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.
    • 24 Nov 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
    • 25 Sep 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top